Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for Maravai Lifesciences Holdings (MRVI) over the last 7 years, with Q3 2025 value amounting to $144.7 million.

  • Maravai Lifesciences Holdings' Shares Outstanding (Weighted Average) rose 220.97% to $144.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $144.7 million, marking a year-over-year increase of 220.97%. This contributed to the annual value of $137.9 million for FY2024, which is 453.84% up from last year.
  • According to the latest figures from Q3 2025, Maravai Lifesciences Holdings' Shares Outstanding (Weighted Average) is $144.7 million, which was up 220.97% from $144.2 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Shares Outstanding (Weighted Average) ranged from a high of $144.7 million in Q3 2025 and a low of $96.6 million during Q1 2021
  • Its 5-year average for Shares Outstanding (Weighted Average) is $130.3 million, with a median of $131.9 million in 2023.
  • The largest annual percentage gain for Maravai Lifesciences Holdings' Shares Outstanding (Weighted Average) in the last 5 years was 100898.46% (2021), contrasted with its biggest fall of 6193.76% (2021).
  • Over the past 5 years, Maravai Lifesciences Holdings' Shares Outstanding (Weighted Average) (Quarter) stood at $114.8 million in 2021, then grew by 14.6% to $131.5 million in 2022, then increased by 0.28% to $131.9 million in 2023, then increased by 4.54% to $137.9 million in 2024, then grew by 4.91% to $144.7 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $144.7 million in Q3 2025, compared to $144.2 million in Q2 2025 and $143.4 million in Q1 2025.